WEBULL
News
ATRX
0.0001
NaN%
--
Weekly Report: what happened at ATRX last week (0112-0116)?
Weekly Report · 7h ago
Weekly Report: what happened at ATRX last week (0105-0109)?
Weekly Report · 01/12 10:17
Weekly Report: what happened at ATRX last week (1229-0102)?
Weekly Report · 01/05 10:12
Weekly Report: what happened at ATRX last week (1222-1226)?
Weekly Report · 12/29/2025 10:11
Weekly Report: what happened at ATRX last week (1215-1219)?
Weekly Report · 12/22/2025 10:11
Weekly Report: what happened at ATRX last week (1208-1212)?
Weekly Report · 12/15/2025 10:18
Weekly Report: what happened at ATRX last week (1201-1205)?
Weekly Report · 12/08/2025 10:16
Weekly Report: what happened at ATRX last week (1124-1128)?
Weekly Report · 12/01/2025 10:12
Weekly Report: what happened at ATRX last week (1117-1121)?
Weekly Report · 11/24/2025 10:17
Weekly Report: what happened at ATRX last week (1110-1114)?
Weekly Report · 11/17/2025 10:17
Weekly Report: what happened at ATRX last week (1103-1107)?
Weekly Report · 11/10/2025 10:14
Weekly Report: what happened at ATRX last week (1027-1031)?
Weekly Report · 11/03/2025 10:15
Weekly Report: what happened at ATRX last week (1020-1024)?
Weekly Report · 10/27/2025 10:18
Weekly Report: what happened at ATRX last week (1013-1017)?
Weekly Report · 10/20/2025 10:15
Weekly Report: what happened at ATRX last week (1006-1010)?
Weekly Report · 10/13/2025 10:17
Weekly Report: what happened at ATRX last week (0929-1003)?
Weekly Report · 10/06/2025 10:14
Weekly Report: what happened at ATRX last week (0922-0926)?
Weekly Report · 09/29/2025 10:15
Weekly Report: what happened at ATRX last week (0915-0919)?
Weekly Report · 09/22/2025 10:15
Weekly Report: what happened at ATRX last week (0908-0912)?
Weekly Report · 09/15/2025 11:45
Weekly Report: what happened at ATRX last week (0901-0905)?
Weekly Report · 09/08/2025 11:47
More
Webull provides a variety of real-time ATRX stock news. You can receive the latest news about Adhera Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ATRX
Adhera Therapeutics, Inc. is a specialty biotech company. The Company is focused on the drug development and commercialization of small molecule drugs to treat Parkinson's disease (PD) and Type 1 diabetes. The Company has two drug candidates: MLR-1019 and MLR-1023. It is engaged in developing MLR-1023 (tolimidone) as a new drug for Type I Diabetes with a focus on C-peptide positive patients. Adhera also has exclusive rights to develop MLR-1023 for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation diseases and conditions. MLR-1023, a lyn kinase activator, has demonstrated clinical safety and tolerability in over 700 patients in Phase IIa and Phase IIb Type 2 diabetes studies. MLR-1019 (armesocarb) is a new class of drug for Parkinson's Disease.